Gene
JAK3
JAK3 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (12), Actionable biomarkers (2), Trial mentions (12), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention JAK3. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 27 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 1 of 8,738 | 0.01% | not measured | |
| 2025 | 1 of 8,875 | 0.01% | not measured | |
| 2024 | 2 of 8,597 | 0.02% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 33 of 11,460 | 0.29% |
| 2022 | 0 of 8,285 | 0.00% | 42 of 13,598 | 0.31% |
| 2021 | 1 of 8,692 | 0.01% | 52 of 15,045 | 0.35% |
| 2020 | 0 of 7,640 | 0.00% | 35 of 14,459 | 0.24% |
| 2019 | 2 of 7,300 | 0.03% | 28 of 12,159 | 0.23% |
| 2018 | 2 of 6,927 | 0.03% | 29 of 11,854 | 0.24% |
| 2017 | 1 of 6,558 | 0.02% | 22 of 11,595 | 0.19% |
Showing 10 of 37 years.
Assay-provider ledger (12)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| GeneChem | Reagent supplier | Analytical validation | 1 | May 01, 2022 |
| HIS/BIOO Scientific Corporation | Reagent supplier | Analytical validation | 1 | April 01, 2018 |
| Illumina | Unclassified | Analytical validation | 2 | April 01, 2018 |
| Promega | Reagent supplier | Analytical validation | 1 | April 01, 2018 |
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 3 | April 01, 2018 |
Showing 5 of 12 assay-provider companies.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| JAK3 (R657Q,I87T,Q501H) | Jak Inhibitors | response-associated | adult acute megakaryoblastic leukemia | Cancer Genome Interpreter |
| JAK3 (A572V,A573V) | Jak Inhibitors | response-associated | lymphoma | Cancer Genome Interpreter |
Trial mentions (12)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04370795 | Trial eligibility (AACT) |
| NCT03452774 | Trial eligibility (AACT) |
| NCT02494882 | Trial eligibility (AACT) |
| NCT03519464 | Trial eligibility (AACT) |
| NCT03601819 | Trial eligibility (AACT) |
Showing 5 of 12 trial mentions.
Target-disease associations (801)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 22q11.2 deletion syndrome | cardiovascular disease | Mouse knockout (IMPC) |
| AXIN2-related attenuated familial adenomatous polyposis | cancer or benign tumor | Mouse knockout (IMPC) |
| Aarskog-Scott syndrome, X-linked | genetic, familial or congenital disease | Literature (Europe PMC) |
| Acute hepatic failure | phenotype | Expression Atlas |
| Adrenal Gland Neuroblastoma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 801 associations.
Vendor sourcing (46)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | Frameshift: predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple path... | View ClinVar record SCV002318887.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV000604052.2 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.757A>G (p.T253A) alteration is located in exon 6 (coding exon 5) of the JAK3 gene. This alteration results from a A to G substitution at nucleotide pos... | View ClinVar record SCV003533123.2 |
| Center for International Blood and Marrow Transplant Research | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1\. Infants with SCID, either typical or leaky or Omenn syndrome. 1. Typical SCID is defined as either of the following * Absence or very low number ... | View trial NCT03619551 |
| Center for International Blood and Marrow Transplant Research | Trial sponsor | Mentioned in trial textTrial free-text mention | JAK3 | View trial NCT03619551 |
Showing 5 of 46 sourcing records.
Trial-cited literature (399)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib. | Dermatology and therapy | 2026 | 0 |
| Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia. | Blood neoplasia | 2026 | 0 |
| A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2026 | 0 |
| Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata. | The British journal of dermatology | 2025 | 34 |
| Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme. | Journal of the European Academy of Dermatology and Venereology : JEADV | 2025 | 24 |
Showing 5 of 399 papers.
Protein variant mentions (29)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A1090S | 1 | 2012 | PMID 22980976 |
| p.A527V | 1 | 2015 | PMID 25980440 |
| p.A573V | 1 | 2025 | PMID 40199606 |
| p.A877V | 1 | 2018 | PMID 29217778 |
| p.C565* | 1 | 1995 | PMID 7481768 |
Showing 5 of 29 variants.
Human sample screening reference (2)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.A573V | TCGA-DLBC | Not Reported; Mature B-Cell Lymphomas; Colon; Stomach; Connective, subcutaneous and other soft tissues; Testis; Brain; Heart, mediastinum, and pleura; Other and unspecified major salivary glands; Breast; Small intestine; Bones, joints and articular cartilage of other and unspecified sites; Retroperitoneum and peritoneum; Thyroid gland; Lymph nodes; Hematopoietic and reticuloendothelial systems | 1 | 50 | 2.00% | 0.35% to 10.50% |
| p.A573V | TCGA-UCEC | Not Reported; Epithelial Neoplasms, NOS; Adenomas and Adenocarcinomas; Cystic, Mucinous and Serous Neoplasms; Corpus uteri; Uterus, NOS | 1 | 559 | 0.18% | 0.03% to 1.01% |
Literature-extracted relations (47)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Leukemia, Prolymphocytic, T-Cell | Disease | associate |
Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia. | 2026 |
| Alopecia Areata | Disease | associate |
Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata. | 2025 |
| Carcinoma, Hepatocellular | Disease | associate |
Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata. | 2025 |
| Lymphoma, T-Cell, Peripheral | Disease | associate |
<i>JAK3</i> <sup>A573V</sup> and <i>JAK3</i> <sup>M511I</sup> mutations in peripheral T-cell lymphoma mediating resistance to anti-PD-1 therapy through the STAT3/PD-L1 pathway. | 2025 |
| Alopecia Areata | Disease | associate |
The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Ritlecitinib, a Janus Kinase 3 and Tyrosine-Protein Kinase Family Inhibitor, in Humans. | 2024 |
Showing 5 of 47 relation assertions.
Organizations publishing (369)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 28 | 1995 to 2023 |
| University of California System | Academic | 17 | 2011 to 2024 |
| Oregon Health & Science University | Academic | 13 | 2009 to 2022 |
| University of London | Academic | 12 | 2008 to 2024 |
| Boston Children's Hospital | Hospital | 11 | 2014 to 2022 |
Showing 5 of 369 organizations.
Where JAK3 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- medical procedure
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
712 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.